Posts by:
Today we would like to share another exciting development in the field of canine oncology genetics and precision therapeutics from our manuscript "Shared Hotspot Mutations in Oncogenes Position Dogs as an Unparalleled Comparative Model for Precision Therapeutics," recently published in Scientific Reports.
In our relentless pursuit of advancements in veterinary oncology, the FidoCure Team's research has taken center stage, offering an in-depth exploration into the realm of canine osteosarcoma. The use of real-world data and machine learning techniques promises to provide invaluable insights into the mutation patterns and treatment outcomes associated with this challenging condition.
Genetic Signatures in Canine Mammary Tumors: insights from BRCA1 mutations
At the AACR 2023 annual meeting, Dr. Lucas Rodrigues, Head of Veterinary Research at FidoCure®, presented the results of two innovative studies which demonstrated the power of real-world data from dogs with cancer to drive drug development strategies and inform human clinical trials.
The first study, titled "High frequency of TP53 mutations in canine skin tumors recapitulates solar induced human lesions representing an important research model of spontaneous diseases," focused on the similarities between skin tumors in dogs and humans caused by sun exposure. The study found a high frequency of TP53 mutations in canine skin tumors, mirroring those seen in humans with solar-induced skin lesions. This validates the use of dogs as a valuable research model for spontaneous diseases.
